• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23760 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial and economic evaluation of family therapy vs. treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Promoting mental well-being in children and adolescents]
2022     Penn Medicine Center for Evidence-based Practice (CEP) Patient bias against healthcare providers
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2022     HTA South [Conductive education in cerebral palsy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy in selected orthopedic conditions]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Dapagliflozin for chronic kidney disease
2022     HTA South [Is there a difference in outcome between closing the palate in one or two stages?]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with urinary and/or fecal incontinence]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis by alteplase for acute ischemic stroke
2022     HTA South [Blood group matching with genotyping]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological Treatment for Postpartum Depression]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [OncotypeDX in breast cancer]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Vistaseal™ – Intraoperative bleeding]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Coronary intravascular lithotripsy in coronary artery disease]
2022     NIHR Health Technology Assessment programme Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions – Part 1: Urinary incontinence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Intensity-modulated radiotherapy for prostate cancer]
2022     Health Information and Quality Authority (HIQA) Catalogue of institutions undertaking COVID-19 horizon scanning
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography angiography in vascular eye diseases]
2022     Institute for Clinical and Economic Review (ICER) Medications for obesity management: effectiveness and value
2022     Health Information and Quality Authority (HIQA) Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Ultrasound therapy for scar tissue]
2022     Institute for Clinical and Economic Review (ICER) AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022     National Institute for Health and Care Excellence (NICE) Cabotegravir with rilpivirine for treating HIV-1. NICE technology appraisal guidance 757
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Advanced lymphoedema: can non-medicinal procedures relieve symptoms?]
2022     Ontario Health First-trimester screening program for the risk of pre-eclampsia using a multiple-marker algorithm: a health technology assessment
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacotherapy in the treatment of obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Diamine oxidase activity test for histamine intolerance]
2022     Institute for Clinical and Economic Review (ICER) Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects [updated Sept 29, 2023]
2022     National Institute for Health and Care Excellence (NICE) Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy. NICE technology appraisal guidance 758
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for head and neck cancer]
2022     National Institute for Health and Care Excellence (NICE) Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 760
2022     Andalusian Health Technology Assessment Area (AETSA) Electro-hipertermia modulada en pacientes con cáncer de páncreas, cáncer colorrectal avanzado y gliomas malignos
2022     NIHR Health Technology Assessment programme Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Phakic intraocular lenses for high-grade myopia]
2022     National Institute for Health and Care Excellence (NICE) Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 761
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Depression in children and adolescents: does psychotherapy lead to better results compared to other therapies?]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Portable home hemodialysis systems]
2022     Center for Drug Evaluation (CDE) First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating devices]
2022     National Institute for Health and Care Excellence (NICE) Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal). NICE technology appraisal guidance 762
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cystitis: do herbal remedies help with recurring, uncomplicated cystitis?]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 1 - overview of heart and lung transplantation in Québec]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - vascular, cardiovascular and thoracic surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for melanoma treatment in adults]
2022     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 763
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Heart disease in children: can children be helped to cope with their illness through psychological support?]
2022     NIHR Health Technology Assessment programme Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at commerce in controlling the spread of COVID-19]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - otolaryngology and oral, maxillofacial and head and neck surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in non-small-cell lung cancer]
2022     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2021
2022     National Institute for Health and Care Excellence (NICE) Fremanezumab for preventing migraine. NICE technology appraisal guidance 764
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Social isolation in the elderly: what measures can prevent or counteract social isolation?]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at workplaces in controlling the spread of COVID-19]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - eye surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for patients with clear-cell renal-cell carcinoma]
2022     Institute for Clinical and Economic Review (ICER) California unsupported price increase report; an evaluation of drug price increases during 2020 in California
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 765
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blood values: do older people benefit from regular determination of vitamin B12 and vitamin D levels in the blood?]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: revision of criteria for the withholding and termination of resuscitation by paramedics in prehospital setting]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for advanced or metastatic urothelial carcinoma]
2022     Institute for Clinical and Economic Review (ICER) The next generation of rare disease drug policy: ensuring both innovation and affordability
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. NICE technology appraisal guidance 766
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mobility disorders: does the Feldenkrais method help?]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Subcutaneous implantable cardioverter-defibrillator (S-ICD). Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE)
2022     National Institute for Health and Care Excellence (NICE) Ponesimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 767
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous transvascular implantation of a coronary sinus reducing stent. Update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 3 - overview of renal and pancreatic transplantation in Québec]
2022     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 768
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Developmental vision disorders: do children and adolescents benefit from active vision training?]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for the treatment of primary membranous nephropathy
2022     Austrian Institute for Health Technology Assessment (AIHTA) Hepatic and portal vein embolisation prior to major hepatectomy
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2022     National Institute for Health and Care Excellence (NICE) Palforzia for treating peanut allergy in children and young people. NICE technology appraisal guidance 769
2022     Austrian Institute for Health Technology Assessment (AIHTA) Microwave ablation for liver tumours
2022     Austrian Institute for Health Technology Assessment (AIHTA) Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 770
2022     NIHR Health Technology Assessment programme Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT
2022     Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 771
2022     Austrian Institute for Health Technology Assessment (AIHTA) Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer
2022     NIHR Health Technology Assessment programme SeHCAT (tauroselcholic [75selenium] acid) for the investigation of bile acid diarrhoea in adults: a systematic review and cost-effectiveness analysis
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. NICE technology appraisal guidance 772
2022     Austrian Institute for Health Technology Assessment (AIHTA) Lower esophageal sphincter devices for laparoscopic surgery in patients with gastroesophageal reflux disease (GERD)
2022     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 773
2022     Health Information and Quality Authority (HIQA) International review of clinical guidelines and models of care for long COVID
2022     Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022     Belgian Health Care Knowledge Centre (KCE) Evaluation of Shingrix vaccine against herpes zoster
2022     National Institute for Health and Care Excellence (NICE) Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal). NICE technology appraisal guidance 774
2022     Health Information and Quality Authority (HIQA) Update processes for guidelines – systematic review
2022     Health Technology Wales (HTW) Extreme hypofractionated radiotherapy (EHFRT) for localised prostate cancer